Latest Nutra Pharma Corp (NPHC) Headlines Glo
Post# of 102
Posted On: 03/10/2014 7:41:19 PM
Latest Nutra Pharma Corp (NPHC) Headlines
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myasthenia Gravis - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz5swx/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H2 2013" report to their offering. 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. Scope - A snapshot of the global therapeutic scenario for Myasthenia Gravis. - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned GlaxoSmithKline plc Grifols, S.A. Astellas Pharma Inc. Nutra Pharma Corporation Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Cytokinetics, Incorporated HanAll Biopharma Co., Ltd. CuraVac, Inc. Biokine Therapeutics Ltd. Toleranzia AB Varleigh Immuno-Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/rz...nia_gravis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
Marketwire - Tue Jan 07, 8:34AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma previously announced the launch of the MyNyloxin website that allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC") program, Front Street Capital 2004 (the "Manager") has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund").
Nutra Pharma's network marketing distributor partner launches MyNyloxin.com for Nyloxin sales
M2 - Mon Dec 09, 4:45AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) announced on Friday that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin, in the Network Marketing channel is launching its distributor website at http://www.mynyloxin.com over the coming weekend.
Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
Marketwire - Fri Dec 06, 1:23PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel is launching their distributor website http://www.mynyloxin.com over the coming weekend. The website will allow for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma Corp provides exclusive distribution rights to MyNyloxin for the OTC pain reliever Nyloxin
M2 - Tue Dec 03, 4:31AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) stated on Monday that it has granted the exclusive rights to market and distribute its over-the-counter (OTC) pain reliever, Nyloxin, to new Network Marketing company MyNyloxin.
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
Marketwire - Mon Dec 02, 7:01AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company, will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwire - Mon Nov 18, 1:39PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), will be presenting at the upcoming Undiscovered Equities Conference in Boca Raton, Florida on Thursday, November 21, 2013. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers; Nyloxin(R), Pet Pain-Away, Cobroxin(R) and Equine Nyloxin(R).
News and Updates on AXPW, HEMP and NPHC
ACCESSWIRE - Tue Nov 12, 9:30AM CST
News and Updates on Axion Power International Inc. (OTC:AXPW), Hemp Inc (OTC:HEMP) and Nutra Pharma Corporation (OTC:NPHC).
Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin(R)
Marketwire - Mon Nov 11, 7:00AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has begun filming commercials to begin their advertising campaign for the Company's all-natural, non-addictive pain reliever -- Nyloxin(R).
In Depth Stock Reports On ITEN, PGLC and NPHC
ACCESSWIRE - Tue Nov 05, 12:02AM CST
CodeSmart Holdings Inc (OTC: ITEN), Pershing Gold Corp (OTC
GLC) and Nutra Pharma Corp (OTC: NPHC) have been added to our watchlist.
Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in Horses
Marketwire - Wed Oct 30, 7:02AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they are in the process of launching the newest addition to their line of homeopathic treatments for chronic pain, Equine Nyloxin(R).
New Small Cap Stock Reports on NPHC, LQMT and GTXI
ACCESSWIRE - Tue Oct 29, 12:26AM CDT
Nutra Pharma Corporation (OTC: NPHC), Liquidmetal Technologies, Inc. (OTC: LQMT) and GTx, Inc., (NASDAQ: GTXI) are our New Small Cap Stock Reports today.
Nutra Pharma Announces Updated Interviews With Wall Street Buy Sell Hold
Marketwire - Tue Oct 22, 7:02AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik J Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is an update to the previous one posted in August and provides an outline for the short, mid-term and long-term goals of the company. Castaldo also updated his interview with Jonathan Flicker, the CEO of Nutra Pharma's Nyloxin(R) Distributor, New Vitality.
Nutra Pharma Announces TCN's Full Launch of Their Nyloxin(R) Distribution Model
Marketwire - Tue Oct 08, 7:31AM CDT
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R).
Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myasthenia Gravis - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz5swx/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H2 2013" report to their offering. 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. Scope - A snapshot of the global therapeutic scenario for Myasthenia Gravis. - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned GlaxoSmithKline plc Grifols, S.A. Astellas Pharma Inc. Nutra Pharma Corporation Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Cytokinetics, Incorporated HanAll Biopharma Co., Ltd. CuraVac, Inc. Biokine Therapeutics Ltd. Toleranzia AB Varleigh Immuno-Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/rz...nia_gravis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
Marketwire - Tue Jan 07, 8:34AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma previously announced the launch of the MyNyloxin website that allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC") program, Front Street Capital 2004 (the "Manager") has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund").
Nutra Pharma's network marketing distributor partner launches MyNyloxin.com for Nyloxin sales
M2 - Mon Dec 09, 4:45AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) announced on Friday that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin, in the Network Marketing channel is launching its distributor website at http://www.mynyloxin.com over the coming weekend.
Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
Marketwire - Fri Dec 06, 1:23PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel is launching their distributor website http://www.mynyloxin.com over the coming weekend. The website will allow for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma Corp provides exclusive distribution rights to MyNyloxin for the OTC pain reliever Nyloxin
M2 - Tue Dec 03, 4:31AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) stated on Monday that it has granted the exclusive rights to market and distribute its over-the-counter (OTC) pain reliever, Nyloxin, to new Network Marketing company MyNyloxin.
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
Marketwire - Mon Dec 02, 7:01AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company, will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwire - Mon Nov 18, 1:39PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), will be presenting at the upcoming Undiscovered Equities Conference in Boca Raton, Florida on Thursday, November 21, 2013. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers; Nyloxin(R), Pet Pain-Away, Cobroxin(R) and Equine Nyloxin(R).
News and Updates on AXPW, HEMP and NPHC
ACCESSWIRE - Tue Nov 12, 9:30AM CST
News and Updates on Axion Power International Inc. (OTC:AXPW), Hemp Inc (OTC:HEMP) and Nutra Pharma Corporation (OTC:NPHC).
Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin(R)
Marketwire - Mon Nov 11, 7:00AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has begun filming commercials to begin their advertising campaign for the Company's all-natural, non-addictive pain reliever -- Nyloxin(R).
In Depth Stock Reports On ITEN, PGLC and NPHC
ACCESSWIRE - Tue Nov 05, 12:02AM CST
CodeSmart Holdings Inc (OTC: ITEN), Pershing Gold Corp (OTC
GLC) and Nutra Pharma Corp (OTC: NPHC) have been added to our watchlist. Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in Horses
Marketwire - Wed Oct 30, 7:02AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they are in the process of launching the newest addition to their line of homeopathic treatments for chronic pain, Equine Nyloxin(R).
New Small Cap Stock Reports on NPHC, LQMT and GTXI
ACCESSWIRE - Tue Oct 29, 12:26AM CDT
Nutra Pharma Corporation (OTC: NPHC), Liquidmetal Technologies, Inc. (OTC: LQMT) and GTx, Inc., (NASDAQ: GTXI) are our New Small Cap Stock Reports today.
Nutra Pharma Announces Updated Interviews With Wall Street Buy Sell Hold
Marketwire - Tue Oct 22, 7:02AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik J Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is an update to the previous one posted in August and provides an outline for the short, mid-term and long-term goals of the company. Castaldo also updated his interview with Jonathan Flicker, the CEO of Nutra Pharma's Nyloxin(R) Distributor, New Vitality.
Nutra Pharma Announces TCN's Full Launch of Their Nyloxin(R) Distribution Model
Marketwire - Tue Oct 08, 7:31AM CDT
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R).
Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Nutra Pharma Corp. (NPHC) Stock Research Links
Scroll down for more posts ▼